Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | 35,1x - 38,8x | 36,9x |
| Selected Fwd EBIT Multiple | 28,9x - 31,9x | 30,4x |
| Fair Value | ₹2.224 - ₹2.445 | ₹2.335 |
| Upside | -19,9% - -11,9% | -15,9% |
| Benchmarks | Ticker | Full Ticker |
| Lupin Limited | 500257 | BSE:500257 |
| Alembic Pharmaceuticals Limited | 533573 | BSE:533573 |
| Medico Remedies Limited | 540937 | BSE:540937 |
| Zydus Lifesciences Limited | 532321 | BSE:532321 |
| Glenmark Pharmaceuticals Limited | 532296 | BSE:532296 |
| GlaxoSmithKline Pharmaceuticals Limited | GLAXO | NSEI:GLAXO |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| 500257 | 533573 | 540937 | 532321 | 532296 | GLAXO | ||
| BSE:500257 | BSE:533573 | BSE:540937 | BSE:532321 | BSE:532296 | NSEI:GLAXO | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | 10.1% | -2.3% | 39.4% | 13.7% | 2.8% | 8.5% | |
| 3Y CAGR | 16.5% | -20.1% | 40.8% | 18.4% | -5.6% | 17.3% | |
| Latest Twelve Months | 71.4% | 17.0% | 15.2% | 28.6% | 132.5% | 35.3% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | 10.1% | 14.7% | 4.4% | 18.9% | 13.6% | 22.0% | |
| Prior Fiscal Year | 5.1% | 7.7% | 4.9% | 16.6% | 9.8% | 23.0% | |
| Latest Fiscal Year | 13.9% | 10.6% | 6.9% | 23.2% | 11.4% | 24.3% | |
| Latest Twelve Months | 18.8% | 11.2% | 6.6% | 24.6% | 18.7% | 27.8% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 4.09x | 2.89x | 3.00x | 3.97x | 3.05x | 12.21x | |
| EV / LTM EBITDA | 17.7x | 19.2x | 36.1x | 14.2x | 13.9x | 42.1x | |
| EV / LTM EBIT | 21.7x | 25.9x | 45.4x | 16.1x | 16.3x | 43.9x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | 16.1x | 21.7x | 45.4x | ||||
| Historical EV / LTM EBIT | 28.2x | 35.1x | 41.1x | ||||
| Selected EV / LTM EBIT | 35.1x | 36.9x | 38.8x | ||||
| (x) LTM EBIT | 10,313 | 10,313 | 10,313 | ||||
| (=) Implied Enterprise Value | 361,560 | 380,589 | 399,619 | ||||
| (-) Non-shareholder Claims * | 20,960 | 20,960 | 20,960 | ||||
| (=) Equity Value | 382,520 | 401,550 | 420,579 | ||||
| (/) Shares Outstanding | 169.4 | 169.4 | 169.4 | ||||
| Implied Value Range | 2,258.01 | 2,370.34 | 2,482.67 | ||||
| FX Rate: INR/INR | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 2,258.01 | 2,370.34 | 2,482.67 | 2,776.60 | |||
| Upside / (Downside) | -18.7% | -14.6% | -10.6% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | 500257 | 533573 | 540937 | 532321 | 532296 | GLAXO | |
| Enterprise Value | 922,675 | 183,372 | 4,567 | 873,761 | 427,488 | 449,412 | |
| (+) Cash & Short Term Investments | 29,123 | 1,290 | 15 | 24,950 | 18,202 | 21,108 | |
| (+) Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Debt | (34,425) | (10,664) | (114) | (1,905) | (17,808) | (148) | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 917,373 | 173,998 | 4,468 | 896,806 | 427,882 | 470,373 | |
| (/) Shares Outstanding | 456.5 | 196.6 | 83.0 | 1,006.2 | 282.2 | 169.4 | |
| Implied Stock Price | 2,009.40 | 885.20 | 53.84 | 891.25 | 1,516.30 | 2,776.60 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 2,009.40 | 885.20 | 53.84 | 891.25 | 1,516.30 | 2,776.60 | |
| Trading Currency | INR | INR | INR | INR | INR | INR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |